glp-1 optimization receptor agonists and surgical care: implications for bariatric Procedures, perioperative Outcomes, and nutritional 1 pathways Designing GLP-1 delivery: structural perspectives

Currently, UDCA is not recommend for NASH treatment in the guidelines [5,6,7,8]

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

doi: 10.1210/jc.2012-1595 206 HirschHJEldar-GevaTBennarochFPollakYGross-TsurV

The score drops due to higher visit costs, no medication shipping, limited GLP-1s, and the absence of coaching even though the care team offers basic lifestyle support

So the lifetime cost of a treatment taken for years and years and years is not that different from the lifetime cost of the gene therapy